drugset / Trial / NCT00254137
Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.
Phase 2
Completed
92 enrolled
Ludwig-Maximilians - University of Munich
Hoffmann-La Roche · collabMerck Sharp & Dohme LLC · collabPfizer · collabSanofi · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |